Target intelligence / Profile preview

PMS1 protein homolog 1 (PMS1) (PMS1)

Target
PMS1
Molecular classification
DNA mismatch repair protein, ATPase, MutL homolog, Enzyme
01

Overview

PMS1 protein homolog 1 (PMS1) is a member of the MutL homolog family and a vital component of the eukaryotic DNA mismatch repair (MMR) system (UniProt P54277). It functions primarily by forming a heterodimer with MLH1, known as MutLβ, which participates in the recognition and repair of DNA base-pair mismatches and insertion-deletion loops generated during DNA replication (GeneCards; Wikipedia). Beyond its canonical role in maintaining genomic stability, PMS1 has recently emerged as a significant therapeutic target for Huntington's disease and other trinucleotide repeat expansion disorders (Nature Communications, 2024, 15:3182). Research indicates that PMS1 is a key driver of somatic CAG repeat expansion, and its downregulation can slow the progression of these neurodegenerative conditions (Nature Communications, 2024, 15:3182). Small-molecule splice modulators, including branaplam and risdiplam, have been shown to target PMS1 by inducing the inclusion of a premature stop codon-containing pseudoexon, leading to reduced protein expression (BioWorld, 2025; Nature Communications, 2024). While therapeutic modulation of PMS1 offers a novel approach to treating repeat expansion diseases, it also presents challenges such as the potential for increased systemic mutation rates and an associated risk of malignancies like Lynch syndrome (GeneCards; PubMed 8128251).

Other names
PMSL1HNPCC3MLH2hPMS1Postmeiotic segregation increased 1Mismatch repair system component PMS1
02

Mechanism of action

Splice modulation via the induction of a frame-shifting pseudoexon containing a premature stop codon, leading to the downregulation of PMS1 protein levels (Nature Communications, 2024, 15:3182; BioWorld, 2025).

03

Biological functions

DNA mismatch repairDNA bindingATP binding5mC deamination repairCellular response to DNA damage
04

Disease associations

Lynch syndromeColorectal cancerHuntington's diseaseNeurodegenerative diseaseHereditary nonpolyposis colorectal cancer type 3 (HNPCC3)
05

Safety considerations

Increased systemic mutation rate (mutator phenotype)Potential predisposition to malignancies (Lynch syndrome association)Off-target splicing effects
06

Interacting drugs

Branaplam

2 more in the full profile.

07

Biomarkers

Microsatellite instability (MSI)PMS1 protein expression levelsSomatic CAG repeat expansion rate

Beyond the preview

Go deeper on PMS1 protein homolog 1 (PMS1) (PMS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS1 protein homolog 1 (PMS1) (PMS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call